Catalyst Pharma Gains, Teva Patent Settlement Seen Positive (1)

(Updates trading, adds analyst comment.)

Catalyst Pharmaceuticals shares are up 14% after settling a patent litigation case with Teva Pharmaceutical. Shares of Teva are unchanged.

• Oppenheimer writes that “this outcome comes in above our expectations,” adding that “uncertainty around this topic had kept many on the sidelines and that today’s update will facilitate investor interest in CPRX”
  • Analyst Leland Gershell expects other challengers to reach similar agreements, “effectively resulting in Firdapse enjoying more than nine years of market protection beyond its November 2025 FDA orphan expiration”
  • Outperform, PT $29

More detail:

• Teva gets a license to market generic FIRDAPSE in ...